RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancerKey one (1) year biomarker and safety findings of ONCY's Phase 2 Bracelet-1 breast cancer study:
Association between T cell expansion and efficacy measures:
A statistically significant increase in T cell fraction, a measure of T cell expansion, was observed in cohort 2 (paclitaxel + pelareorep) but not cohort 3 (paclitaxel + pelareorep + avelumab)
Generally favorable and manageable safety profile:
Pelareorep displayed a manageable safety profile consistent with what has been observed in prior clinical trials that have collectively treated over 1,100 patients
Dr. Thomas Heineman, Chief Medical Officer, commented, "BRACELET-1's impressive initial results are maturing quite favorably.
While five patients in the pelareorep-paclitaxel group had partial responses at week 16, six patients in total had confirmed responses. This includes two patients who improved from stable disease to partial responses at later times, consistent with pelareorep's immunologic mechanism of action.
Moreover, the compelling ORR and PFS hazard ratio achieved align with translational results showcasing pelareorep's immune-mediated mechanism of action and complement additional data that support the combination therapy's generally favorable safety profile.."